Emerging trend of Biosimilars therapy is expected to propel the growth of solid tumors treatment market
A solid tumor is an abnormal mass or lump of tissues without liquid or cysts. It is not necessary that tumor should always be cancerous. On the basis tumor nature, it can be classified as the malignant tumor (cancerous) and the benign tumor (non-cancerous). Based on the cell type, tumors can be classified as carcinomas, sarcomas, and lymphomas. The Solid tumors might occur in several places such as muscle, bone, and organs. Treatments for solid tumors include prevention of tumor and combination of surgery, chemotherapy, and radiation therapy.
Arising pattern of Biosimilars treatment is relied upon to move the development of solid tumors treatment market
As indicated by information distributed in International Journal of Pharma Sciences and Research (IJPSR) in 2011, there were around 9 million passings because of malignancy. In 2015, 11.4 million individuals are relied upon to bite the dust in 2030, among this pervasiveness of malignant growth greatest is because of solid tumors. Developing commonness of solid tumors is the significant driving component for the development of solid tumors treatment market. Also, some different variables fuelling the development of solid tumors treatment market incorporate neglected interest for malignant growth treatment and rising interest in the innovative work of disease drugs. In any case, expansion in the volume of conventional helpful items, the significant expense of malignancy treatment, and developing medication patent bluff are a portion of the limitations that may upset the development of solid tumors treatment market.
Regional segmentation of Solid Tumors Treatment market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Africa, and the Middle East. North America dominates in the solid tumors treatment market due to the presence of well-established healthcare infrastructure, and rise in the number of solid tumor cases. For instance, According to the data provided by Centers for Disease Control and Prevention (CDC) in 2013 around 230,815 females and 2109 men in the U.S. were diagnosed with breast cancer. Asia Pacific is expected to grow in the solid tumors market due to the increase in healthcare expenditure, rising patient population, medical tourism, and increasing affordability of people in this region.
Key industry players operating solid tumors treatment market include Abbott Laboratories Inc., Biogen Idec Incorporated, AstraZeneca Plc., Johnson & Johnson Company, Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline Plc., Sanofi, and Baxter International Incorporated. Advancements in the cancer therapy such as nanomedicines used for the treatment of cancer might help the industry players to provide effective patient care in the solid tumors treatment.
